- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
ANDA Litigation Settlements
Spring 2013
| Case Name | Drug | Patent No(s). | Publicly Available Terms |
| In re: Nebivolol patent litigation, 12-5026 (N.D. Ill.) | Bystolic® (nebivolol tablets) | 6,545,040 |
Forest Labs., Inc. to give Glenmark Pharma. Ltd. a license to release generic nebivolol either when the FDA approves Glenmark’s ANDA or three months prior to patent expiration, whichever is first. |
| Mallinckrodt LLC v. Apotex, Inc., 12-1087 (D.Del.) | Pennsaid® (diclofenac sodium topical solution) | 8,217,078 | Apotex may release its generic product, a 1.5% by weight solution, 45 days after Mallinckrodt makes its first commercial shipment of Pennsaid 2%, a new version of the drug, or April 1, 2014, whichever comes first. Apotex may also release its 1.5% version earlier under certain unspecified circumstances. |
| Purdue Pharma LP v. Ranbaxy Inc, 10-3734 (S.D.N.Y.) | OcyContin® (oxycodone hydrochloride extended-release tablets) | 7,674,799; 7,674,800; 7,683,072 |
Ranbaxy admits to infringing the asserted patents. Ranbaxy waived possible antitrust or other claims against Purdue.
|
| AstraZeneca Pharma. LP v. Torrent Pharma. Ltd., 10-4205 (D.N.J.) | Seroquel XR® (quetiapine fumarate extended-release tablets) | 5,948,437 |
Torrent admits that AstraZeneca’s patent is enforceable and valid. Torrent agrees not to produce its generic version of the drug until November 2016. |
| Gilead Sciences Inc. v. Teva Pharma. USA Inc., 10-1796 (S.D.N.Y.) | Viread® (tenofovir disoproxil fumarate tablets) | 5,922,695; 5,935,946; 5,977,089; 6,043,230 | Teva will be allowed to launch its generic product in December 2017. |
| Shionogi Pharma. Inc. v. Mylan Inc., 10-0135 (D. Del.) | Fortamet® (metformin hydrochloride extended-release tablets) | 6,099,859; 6,866,866 |
Mylan may launch a generic version of Fortamet on Aug. 1 or earlier under certain conditions. |
| AstraZeneca UK Ltd. v. Watson Pharma. Inc., 10-0915 (D. Del.) | Crestor® (rosuvastatin calcium) | RE37,314 | Actavis is allowed to launch its generic product on May 2, 2016—67 days before the expiration of AstraZeneca’s pediatric exclusivity period. Actavis has conceded the validity and enforceability of the ’314 patent, and has agreed not to further appeal a December decision by the Federal Circuit upholding the validity of the patent. Actavis will pay a fee equal to 39% of the net sales of its rosuvastatin drugs to AstraZeneca for that 67-day early launch period. |
| Allergan Inc. v. Athena Cosmetics Inc., 07-1316 (C.D. Ca.) | Latisse® (bimatoprost ophthalmic solution) | 6,262,105; 7,351,404; 7,388,029 | N/A |
GENERICally Speaking Spring 2013
Related Professionals
Related Publications
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
August 2, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.